Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma

  • Erik Mittra
  • Tarek El-Maghraby
  • Cesar A. Rodriguez
  • Andrew Quon
  • I. Ross McDougall
  • Sanjiv S. Gambhir
  • Andrei IagaruEmail author
Original Article



Only a limited number of studies have evaluated the efficacy of 18F-FDG PET/CT for recurrent cervical carcinoma, which this study seeks to expand upon.


This is a retrospective study of 30 women with cervical carcinoma who had a surveillance PET/CT after initial therapy. Sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were calculated using a 2 × 2 contingency table with pathology results (76%) or clinical follow-up (24%) as the gold standard. The Wilson score method was used to perform 95% confidence interval estimations.


The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value of PET/CT for the detection of local recurrence at the primary site were 93, 93, 93, 86, and 96%, respectively. The same values for the detection of distant metastases were 96, 95, 95, 96, and 95%, respectively. Seventy-one percent of the scans performed in symptomatic patients showed true-positive findings. In comparison, 44% of scans performed in asymptomatic patients showed true-positive findings. But, all patients subsequently had a change in their management based on the PET/CT findings such that the effect was notable. The maximum standardized uptake value ranged from 5 to 28 (average: 13 ± 7) in the primary site and 3 to 23 (average: 8 ± 4) in metastases which were significantly different (p = 0.04).


This study demonstrates favorable efficacy of 18F-FDG PET/CT for identification of residual/recurrent cervical cancer, as well as for localization of distant metastases.


PET/CT 18F-FDG Cervical cancer Restaging Efficacy 



This research was supported in part by NCI ICMIC CA114747 (SSG) and the clinical studies were supported in part by the Doris Duke Foundation and Canary Foundation (SSG).


  1. 1.
    Society AC. Estimated new cancer cases and deaths by sex for all sites, US. 2007. Available from: Accessed 1 Jan 2009.
  2. 2.
    Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, et al. Carcinoma of the cervix uteri. J Epidemiol Biostat 2001;6:7–43.PubMedGoogle Scholar
  3. 3.
    Chou HH, Wang CC, Lai CH, Hong JH, Ng KK, Chang TC, et al. Isolated paraaortic lymph node recurrence after definitive irradiation for cervical carcinoma. Int J Radiat Oncol Biol Phys 2001;51:442–8.PubMedGoogle Scholar
  4. 4.
    Larson DM, Copeland LJ, Stringer CA, Gershenson DM, Malone JM Jr, Edwards CL. Recurrent cervical carcinoma after radical hysterectomy. Gynecol Oncol 1988;30:381–7.CrossRefPubMedGoogle Scholar
  5. 5.
    Pectasides D, Economides N, Bourazanis J, Pozadzizou P, Gogou L, Koutsiouba P, et al. Squamous cell carcinoma antigen, tumor-associated trypsin inhibitor, and carcinoembryonic antigen for monitoring cervical cancer. Am J Clin Oncol 1994;17:307–12.PubMedCrossRefGoogle Scholar
  6. 6.
    Hricak H, Yu KK. Radiology in invasive cervical cancer. AJR Am J Roentgenol 1996;167:1101–8.PubMedGoogle Scholar
  7. 7.
    Yildirim Y, Sehirali S, Avci ME, Yilmaz C, Ertopcu K, Tinar S, et al. Integrated PET/CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings. Gynecol Oncol 2008;108:154–9. Epub 2007 Oct 22.CrossRefPubMedGoogle Scholar
  8. 8.
    Havrilesky LJ, Wong TZ, Secord AA, Berchuck A, Clarke-Pearson DL, Jones EL. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol 2003;90:186–90.CrossRefPubMedGoogle Scholar
  9. 9.
    Sun SS, Chen TC, Yen RF, Shen YY, Changlai SP, Kao A. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer. Anticancer Res 2001;21:2957–61.PubMedGoogle Scholar
  10. 10.
    Umesaki N, Tanaka T, Miyama M, Tokuyama O, Kawamura N, Ogita S, et al. Early diagnosis and evaluation of therapy in postoperative recurrent cervical cancers by positron emission tomography. Oncol Rep 2000;7:53–6.PubMedGoogle Scholar
  11. 11.
    Unger JB, Ivy JJ, Connor P, Charrier A, Ramaswamy MR, Ampil FL, et al. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. Gynecol Oncol 2004;94:212–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Chang TC, Law KS, Hong JH, Lai CH, Ng KK, Hsueh S, et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study. Cancer 2004;101:164–71.CrossRefPubMedGoogle Scholar
  13. 13.
    Wahl RL, Quint LE, Cieslak RD, Aisen AM, Koeppe RA, Meyer CR. “Anatometabolic” tumor imaging: fusion of FDG PET with CT or MRI to localize foci of increased activity. J Nucl Med 1993;34:1190–7.PubMedGoogle Scholar
  14. 14.
    Bar-Shalom R, Yefremov N, Guralnik L, Gaitini D, Frenkel A, Kuten A, et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 2003;44:1200–9.PubMedGoogle Scholar
  15. 15.
    Jover R, Lourido D, Gonzalez C, Rojo A, Gorospe L, Alfonso JM. Role of PET/CT in the evaluation of cervical cancer. Gynecol Oncol 2008;110:S55–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Loft A, Berthelsen AK, Roed H, Ottosen C, Lundvall L, Knudsen J, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol 2007;106:29–34. Epub 2007 May 7.CrossRefPubMedGoogle Scholar
  17. 17.
    Kumar R, Dadparvar S. 18F-fluoro-2-deoxy-D-glucose-positron emission tomography (PET)/PET-computed tomography in carcinoma of the cervix. Cancer 2007;110:1650–3.CrossRefPubMedGoogle Scholar
  18. 18.
    Iyer RB, Balachandran A, Devine CE. PET/CT and cross sectional imaging of gynecologic malignancy. Cancer Imaging 2007; 7 Spec No A:S130–8.Google Scholar
  19. 19.
    Amit A, Beck D, Lowenstein L, Lavie O, Bar Shalom R, Kedar Z, et al. The role of hybrid PET/CT in the evaluation of patients with cervical cancer. Gynecol Oncol 2006;100:65–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Grisaru D, Almog B, Levine C, Metser U, Fishman A, Lerman H, et al. The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies. Gynecol Oncol 2004;94:680–4.CrossRefPubMedGoogle Scholar
  21. 21.
    Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Sugimura K. Performance of FDG-PET/CT for diagnosis of recurrent uterine cervical cancer. Eur Radiol 2008;18:2040–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Sironi S, Picchio M, Landoni C, Galimberti S, Signorelli M, Bettinardi V, et al. Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence. Eur J Nucl Med Mol Imaging 2007;34:472–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Chung HH, Jo H, Kang WJ, Kim JW, Park NH, Song YS, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007;104:529–34.CrossRefPubMedGoogle Scholar
  24. 24.
    Kim EE. Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology. Int J Gynecol Cancer 2004;14:12–22.CrossRefPubMedGoogle Scholar
  25. 25.
    Belhocine T. An appraisal of 18F-FDG PET imaging in post-therapy surveillance of uterine cancers: clinical evidence and a research proposal. Int J Gynecol Cancer 2003;13:228–33.CrossRefPubMedGoogle Scholar
  26. 26.
    Ryu SY, Kim MH, Choi SC, Choi CW, Lee KH. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer. J Nucl Med 2003;44:347–52.PubMedGoogle Scholar
  27. 27.
    Yen TC, See LC, Chang TC, Huang KG, Ng KK, Tang SG, et al. Defining the priority of using 18F-FDG PET for recurrent cervical cancer. J Nucl Med 2004;45:1632–9.PubMedGoogle Scholar
  28. 28.
    Magne N, Chargari C, Vicenzi L, Gillion N, Messai T, Magne J, et al. New trends in the evaluation and treatment of cervix cancer: the role of FDG-PET. Cancer Treat Rev 2008;34:671–81.CrossRefPubMedGoogle Scholar
  29. 29.
    Kitajima K, Murakami K, Yamasaki E, Domeki Y, Kaji Y, Morita S, et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent uterine cancer: comparison with PET and enhanced CT. Eur J Nucl Med Mol Imaging 2009;36:362–72.CrossRefPubMedGoogle Scholar
  30. 30.
    Elst P, Ahankour F, Tjalma W. Management of recurrent cervical cancer. Review of the literature and case report. Eur J Gynaecol Oncol 2007;28:435–41.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Erik Mittra
    • 1
  • Tarek El-Maghraby
    • 2
    • 3
  • Cesar A. Rodriguez
    • 1
  • Andrew Quon
    • 1
  • I. Ross McDougall
    • 1
  • Sanjiv S. Gambhir
    • 1
    • 4
  • Andrei Iagaru
    • 1
    Email author
  1. 1.Division of Nuclear MedicineStanford Hospitals & ClinicsStanfordUSA
  2. 2.Nuclear MedicineCairo UniversityCairoEgypt
  3. 3.Nuclear MedicineSaad Specialist HospitalAl KhobarSaudi Arabia
  4. 4.Division of Nuclear Medicine, Departments of Radiology and BioengineeringStanford Hospital and ClinicsStanfordUSA

Personalised recommendations